Last reviewed · How we verify
Predinisone
Predinisone is a Small molecule drug developed by First Affiliated Hospital of Zhejiang University. It is currently in Phase 2 development.
Prednisone is a medication used to treat various conditions, including Atrial Fibrillation, Diffuse Large B Cell Lymphoma, Relapsed or Refractory Multiple Myeloma, Severe Checkpoint Inhibitor Pneumonitis, and Precursor B-Cell Acute Lymphoblastic Leukemia. It is administered orally as part of clinical trials, often in comparison to a placebo or in conjunction with other treatments such as an ablation procedure.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Predinisone |
|---|---|
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma (PHASE2)
- Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL (PHASE2)
- The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia (NA)
- Selinexor, Cyclophosphamide and Prednisone in Myeloma (PHASE2)
- Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Predinisone CI brief — competitive landscape report
- Predinisone updates RSS · CI watch RSS
- First Affiliated Hospital of Zhejiang University portfolio CI
Frequently asked questions about Predinisone
What is Predinisone?
Who makes Predinisone?
What development phase is Predinisone in?
Related
- Manufacturer: First Affiliated Hospital of Zhejiang University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing